Department of Psychiatry
By Russell Kinsaul Published: Mar. 18, 2024 at 5:55 PM CDT Check out the Healthy Mind Lab’s current study on long COVID! Researchers at Washington University are leading the way to find a treatment for a debilitating condition that affects as many as 16 million Americans.
ST. LOUIS (KMOV) -A clinical trial at the Washington University School of Medicine is studying the impact of an antidepressant on long COVID symptoms.
Specifically, the study is examining whether Fluvoxamine, a medication used to treat depression and obsessive-compulsive disorder, can relieve problems with “brain fog” and other neurological conditions associated with lingering symptoms.
At a Glance On behalf of Eric Lenze, MD, please check this link for a recent publication of ours posted on the NIH website!
WashU receives part of $103 million to address depression, anxiety related to pandemic
For some patients, two different medications better than antidepressant alone
Check out our recent publication on PubMed about our pilot study exploring Ketamine for treatment-resistant depression (TRD)!
Click the title to be sent to the a recent publication on a Healthy Mind Lab study! For the full article – click here
New to clinical research? Check out our guide!
In healthy older adults, neither led to measurable improvements after 6 months, 18 months